Copyright · Trademarks · Patents · Trade Secrets · Publicity

An Intellectual Property Law Journal

Rigorous, plain-English analysis of the decisions shaping intellectual property — paired with practical guides for the founders, creators, and counsel who have to live by them.

  • 306case analyses
  • 83practical guides
  • 5IP disciplines

Plain-English answers for founders and creators — what protection you need, what it costs, and what to do when there's a problem.

Guide

The Creator's Guide to Copyright (2026)

Plain-English copyright for creators: when protection begins, your exclusive rights, when to register, fair use, licensing, and protecting your work online.

Guide

The Startup IP Playbook (2026)

A plain-English guide to startup intellectual property: the four IP types founders own, how to keep the company (not founders) owning it, and what investors check.

AI & Copyright

Bartz v. Anthropic: Transformative Training, Unforgivable Acquisition

Judge Alsup held that training a large language model on books is 'exceedingly transformative' fair use — while refusing to extend that blessing to the pirated library that fed it. The $1.5 billion settlement that followed shows where the real exposure lies.

June 24, 2026
AI & Copyright

Kadrey v. Meta: A Fair-Use Win That Reads Like a Plaintiffs' Brief

Two days after Bartz, Judge Chhabria also found AI training to be fair use — but went out of his way to say the result reflected a failure of advocacy, not a vindication of the practice. His 'market dilution' theory is the doctrine to watch.

June 22, 2026
AI & Copyright

Thomson Reuters v. Ross: The First Refusal of Fair Use in the AI Era

Before the generative-AI rulings, a Delaware court rejected fair use for using copyrighted material to build an AI legal-research tool — and pointedly distinguished the software cases the technology industry had relied upon. Its reach is narrower than its reputation.

June 19, 2026
Enablement & Written Description

Amgen v. Sanofi: The Enablement Tax on Functional Genus Claims

A unanimous Supreme Court invalidated Amgen's antibody patents for failing to enable the full scope of what they claimed. The decision revives a demanding, century-old conception of the patent bargain with particular force in the life sciences.

June 8, 2026